Determining vancomycin clearance in an overweight and obese population

American Journal of Health-System Pharmacy

Volumn 68, Issue 7, 2011, Pages 599-603

  Leong, Julie V B ^a   Boro, Maureen S ^a,b   Winter, Michael E ^b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibiotics; Dosage; Excretion; Hospitals; Methodology; Obesity; Vancomycin; Weight

Indexed keywords

VANCOMYCIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIALYSIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBESITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VETERAN;

EID: 79956023389     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100410     Document Type: Article

References (21)

1. Rybak MJ, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009; 66: 82-98.
2. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adults: summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009; 29:1275-9.
3. Nailor MD, Sobel JD. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect Dis Clin North Am. 2009; 23:965-82.
4. Yang YJ, McBride MV, Rodvold KA et al. Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistant Staphylococcus aureus. Am J Health-Syst Pharm. 2010; 67:1017-24.
5. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am J Health-Syst Pharm. 2005; 62:1596-605. (Pubitemid 41060472)
6. Technical appendix 11 - products most frequently involved in medication errors (all categories). In: Hicks RW, Becker SC, Cousins DD, eds. MEDMARX data report. A report on the relationship of drug names and medication errors in response to the Institute of Medicine's call for action. Rockville, MD: U.S. Pharmacopeia; 2008:396.
7. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: monitoring and patient education. Am J Health-Syst Pharm. 2004; 61:457-71. (Pubitemid 38298188)
8. Vance-Bryan K, Guay DR, Gilliland SS et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother. 1993; 37:436-40. (Pubitemid 23072585)
9. Blouin RA, Bauer LA, Miller DD et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982; 21:575-80. (Pubitemid 12070524)
10. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998; 54:621-5. (Pubitemid 28531423)
11. Leonard AE, Boro MS. Vancomycin pharmacokinetics in middle-aged and elderly men. Am J Hosp Pharm. 1994; 51:798-800. (Pubitemid 24096236)
12. Rushing TA, Ambrose PJ. Clinical application and evaluation of vancomycin dosing in adults. J Pharm Technol. 2001; 17:33-8. (Pubitemid 32298248)
13. Lee E, Winter ME, Boro MS. Comparing two predictive methods for determining serum vancomycin concentrations at a Veterans Affairs medical center. Am J Health-Syst Pharm. 2006; 63:1872-5. (Pubitemid 44477459)
14. Flegal FM, Carroll MD, Ogden CL et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303:235-41.
15. Das SR, Kinsinger LS, Yancy WS Jr et al. Obesity prevalence among veterans at Veterans Affairs medical facilities. Am J Prev Med. 2005; 28:291-4. (Pubitemid 40576236)
16. Boyce EG, Dickerson RN, Cooney GF et al. Creatinine clearance estimation in protein-malnourished patients. Clin Pharm. 1989; 8:721-6. (Pubitemid 19263884)
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.
18. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm. 1974; 8:650-5.
19. Winter ME. Basic clinical pharmacokinetics. 5th ed. Baltimore: Lippincott Williams and Wilkins; 2010:100-1.
20. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981; 9:503-12.
21. Murphy JE, Gillespie DE, Bateman CV. Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health-Syst Pharm. 2006; 63:2365-70. (Pubitemid 44851779)